| Literature DB >> 30659022 |
Qianyu Guo1,2, Vivian Z Li2, Jessica N Nichol2, Fan Huang1,2, William Yang1,2, Samuel E J Preston1,2, Zahra Talat2, Hanne Lefrère3, Henry Yu1,2, Guihua Zhang4, Mark Basik1,2, Christophe Gonçalves2, Yao Zhan1,2, Dany Plourde2, Jie Su2, Jose Torres1,2, Maud Marques2, Sara Al Habyan5, Krikor Bijian2, Frédéric Amant3, Michael Witcher1,2, Fariba Behbod6, Luke McCaffrey1,5, Moulay Alaoui-Jamali1,2, Nadia V Giannakopoulos7, Muriel Brackstone8, Lynne-Marie Postovit4,7, Sonia V Del Rincón9,2, Wilson H Miller9,2,10.
Abstract
The mechanisms by which breast cancers progress from relatively indolent ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) are not well understood. However, this process is critical to the acquisition of metastatic potential. MAPK-interacting serine/threonine-protein kinase 1 (MNK1) signaling can promote cell invasion. NODAL, a morphogen essential for embryogenic patterning, is often reexpressed in breast cancer. Here we describe a MNK1/NODAL signaling axis that promotes DCIS progression to IDC. We generated MNK1 knockout (KO) or constitutively active MNK1 (caMNK1)-expressing human MCF-10A-derived DCIS cell lines, which were orthotopically injected into the mammary glands of mice. Loss of MNK1 repressed NODAL expression, inhibited DCIS to IDC conversion, and decreased tumor relapse and metastasis. Conversely, caMNK1 induced NODAL expression and promoted IDC. The MNK1/NODAL axis promoted cancer stem cell properties and invasion in vitro. The MNK1/2 inhibitor SEL201 blocked DCIS progression to invasive disease in vivo. In clinical samples, IDC and DCIS with microinvasion expressed higher levels of phospho-MNK1 and NODAL versus low-grade (invasion-free) DCIS. Cumulatively, our data support further development of MNK1 inhibitors as therapeutics for preventing invasive disease. SIGNIFICANCE: These findings provide new mechanistic insight into progression of ductal carcinoma and support clinical application of MNK1 inhibitors to delay progression of indolent ductal carcinoma in situ to invasive ductal carcinoma. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30659022 PMCID: PMC6513674 DOI: 10.1158/0008-5472.CAN-18-1602
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701